{"gao_id": "GAO-18-157T", "published": "2017-10-03T12:00:00Z", "released": "2017-10-03T08:00:00Z", "summary": "FDA's expanded access program allows patients with serious or life threatening illnesses access to certain drugs before it has approved them. FDA also requires that manufacturers submit data about adverse reactions to these drugs. We testified that while FDA has provided some guidance to manufacturers, it does not fully explain the few instances when it would use these data on adverse reactions. This may influence...", "title": "Investigational New Drugs: FDA's Expanded Access Program", "topics": ["Prescription drugs", "Physicians", "Medically necessary treatments", "Trials", "Drug development", "Health Care", "Access to health care", "Patient care services", "Websites", "Diseases", "Food and drug legislation", "Drug approvals", "Drugs", "Substance abuse treatment", "Internal controls"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-18-157t", "versions": [{"title": "Full Report (8 pages)", "url": "https://www.gao.gov/assets/gao-18-157t.pdf"}, {"title": "Accessible PDF (9 pages)", "url": "https://www.gao.gov/assets/690/688591.pdf"}]}